Question 1

What is the catalog number for Recombinant Bovine Antithrombin-III (SERPINC1)?

Accepted Answer

The catalog number for Recombinant Bovine Antithrombin-III (SERPINC1) is AP9C446.

Question 2

What sizes are available for Recombinant Bovine Antithrombin-III (SERPINC1)?

Accepted Answer

Recombinant Bovine Antithrombin-III (SERPINC1) is available in the following size(s): 1 mg, 10 µg, 200 µg, 5 mg, 50 µg.

Question 3

How many pack sizes does Recombinant Bovine Antithrombin-III (SERPINC1) come in?

Accepted Answer

Recombinant Bovine Antithrombin-III (SERPINC1) is available in 5 different pack sizes.

Question 4

Is Recombinant Bovine Antithrombin-III (SERPINC1) in stock?

Accepted Answer

Recombinant Bovine Antithrombin-III (SERPINC1) is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

Can I get a trial-size or discounted first order of this product?

Accepted Answer

We don’t generally offer free samples, but trial discounts in exchange for feedback and validation results are almost always possible. Contact us with your intended application to arrange one.

Question 6

Do you offer bulk or custom quantities of this product?

Accepted Answer

Yes. Ordering two or more units, or combining this with other products, usually qualifies for a discount depending on quantity. Contact our sales team with your required volume for a custom quote.

Question 7

Do you provide a Certificate of Analysis (CoA) for this product?

Accepted Answer

A Certificate of Analysis is available for most products upon request. Contact our support team with the lot number to obtain the relevant CoA.

Recombinant Bovine Antithrombin-III (SERPINC1)

Product Specifications

Type

Source

Species

Available Sizes

Frequently Asked Questions

Explore Other Products

RALGAPA1 Polyclonal Antibody

RALGAPA1 Polyclonal Antibody

RALGAPA1 Polyclonal Antibody

RALGAPA1 Polyclonal Antibody

OBFC1 (STN1) Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: OTI2E4]

MSC Human Gene Knockout Kit (CRISPR)